Home › Bell Radar › LYCA

LYCALycia Therapeutics

US ExchangeHealth Care2026-10-23

Clinical-stage biotech developing LYTAC-based therapeutics to degrade disease-causing extracellular proteins.

$18IPO price
$317MRaised
$30Day-1 close
66.67%Day-1 return
Clinical-stage biotech developing LYTAC-based therapeutics to degrade disease-causing extracellular proteins.
Company description (source: StockAnalysis)

Lycia Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. By leveraging our proprietary LYTAC (Lysosomal Targeting Chimera) platform, we have developed a pipeline of therapeutic candidates with the potential to provide deep and durable elimination of extracellular proteins that are inadequately addressed by currently available therapies. ...

生物医药创新药临床阶段
51CFO read: Requires IPO financial modeling for early-stage biotech, FDA/CDER engagement experience, and platform pipeline valuation capability.
Management details per the SEC prospectus.
Company profile SEC prospectus
Does your company need this kind of CFO?

51CFO is an investment banking team focused on the US market: US IPOs, reverse mergers, shell deals, SPAC and De-SPAC, SEC filings and post-listing follow-ons, run by one team from structure to opening bell. Free 30-minute listing-route diagnosis, answered within 24 hours.

Talk to us